Document is current
Any future updates will be listed below
-
Authors
Compte, Emilio J.
McGuire, F. Hunter
Brown, Tiffany A.
Lavender, Jason M.
Murray, Stuart B.
Capriotti, Matthew R.
Flentje, Annesa
Lubensky, Micah E.
Lunn, Mitchell R.
Obedin-Maliver, Juno
Nagata, Jason M.
- License Information
-
More Information
Article History
Received: 16 May 2023
Accepted: 30 August 2023
First Online: 22 September 2023
Declarations
:
: The University of California, San Francisco Institutional Review Board approved this study on 2 February 2018 (#16–21213) and The Stanford University School of Medicine Review Board on 1 February 2019 (#48707). All procedures performed in this study were in accordance with the ethical standards of the university’s Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.
: Not applicable.
: Dr. Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Folx, Inc. (2020—present), and Hims Inc. (2019—present). Dr. Lunn has consulted for Hims Inc. (2019—present) and Folx, Inc. (2020). Dr. Flentje has consulted for Hopelab (2020, 2022). Dr. Capriotti is on the clinical advisory board of Appa Health (2021-present) and received speaking fees and travel support for trainings on behavioral treatments of tic disorders. None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.
